Company profilePharmaceutical#417 of 1,318 in Pakistan✓ No DRAP alerts

ELI LILLY PAKISTAN (PVT) LTD.

Pharmaceutical company · 38 brands · 32 molecules

Ranked #3 of 28 companies in Diabetes

38 registered products 26 pharmaceutical brands 32 distinct molecules 0 DRAP alerts

Company overview

38
registered products
26
pharmaceutical brands
32
distinct molecules
12
therapeutic classes
0
DRAP alerts

ELI LILLY PAKISTAN (PVT) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 38 product registrations across 32 distinct molecules. Its portfolio is concentrated in Diabetes and Neuro. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by ELI

31 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Drugs For Treatment Of Bone Diseases 2
Blood Glucose Lowering Drugs, Excluding Insulin 2

Top molecules by brand count

Human3 brands
Olanzapine2 brands
Insulin Lispro Protamine 75%2 brands
Insulin Lispro 25%2 brands

Therapeutic classes

Diabetes · 9Neuro · 5Insulins And Analogues · 5Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 2Antidepressants · 2Antineoplastics · 2Pituitary And Hypothalamic Hormones And Analogues · 1Hormone Regulators · 1Blood Glucose Lowering Drugs, Excluding Insulin · 1Other Nervous System Drugs · 1Drugs For Treatment Of Bone Diseases · 1Antithrombotic Agents · 1

Conditions treated

Insulins · 9Schizophrenia/Psychosis · 2Anxiety/Depression/Insomnia · 2Hormonal Therapy · 1Adhd · 1

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO18 products · Rs 658.35 – Rs 63,237
Servaid23 products · Rs 755.02 – Rs 15,674
Median across source: Rs 4,695

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GETZ PHARMA PAKISTAN (PVT) LTD. holds 265 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
Novo Nordisk Pharma (Pvt.) Ltd. holds 15 molecules not in this portfolio
AspartDegludecHuman InsulinHuman Insulin RegularHuman Insulin Regular 30%Insulin
NABIQASIM INDUSTRIES (PVT) LTD. holds 194 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAcyclovir

Get the full profile for ELI

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.